Arrowhead Pharmaceuticals, Inc. (ARWR) P/E Ratio History
Historical price-to-earnings valuation from 1999 to 2026
Loading P/E history...
ARWR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a price-to-earnings ratio of -6389.3x, with a stock price of $77.95 and trailing twelve-month earnings per share of $-2.11.
The current P/E is 9880% below its 5-year average of 65.3x. Over the past five years, ARWR's P/E has ranged from a low of 0.6x to a high of 280.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ARWR trades at a 28721% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ARWR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARWR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARWR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 127.0 | - | +207%Best | |
| $74B | 17.1Lowest | 2.70 | +8% | |
| $8B | 25.5 | 1.11Best | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ARWR Historical P/E Data (1999–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | Wed Dec 31 2025 00:00:00 GM | $66.39 | $1.54 | 43.1x | -34% |
| FY2020 Q2 | $28.77 | $0.10 | 280.7x | +330% | |
| FY2020 Q1 | $63.43 | $0.54 | 116.9x | +79% | |
| FY2019 Q4 | Mon Sep 30 2019 00:00:00 GM | $28.18 | $0.70 | 40.3x | -38% |
| FY2019 Q3 | Sun Jun 30 2019 00:00:00 GM | $26.50 | $0.47 | 56.4x | -14% |
| FY2019 Q2 | Sun Mar 31 2019 00:00:00 GM | $18.35 | $0.08 | 229.4x | +251% |
| FY2004 Q3 | Wed Jun 30 2004 00:00:00 GM | $70.00 | $12.51 | 5.6x | -91% |
| FY2004 Q2 | Wed Mar 31 2004 00:00:00 GM | $45.00 | $6.49 | 6.9x | -89% |
| FY2000 Q2 | Fri Mar 31 2000 00:00:00 GM | $121.55 | $50.02 | 2.4x | -96% |
| FY2000 Q1 | Fri Dec 31 1999 00:00:00 GM | $35.75 | $54.51 | 0.7x | -99% |
| FY1999 Q4 | $58.50 | $59.00 | 1.0x | -98% | |
| FY1999 Q3 | Wed Jun 30 1999 00:00:00 GM | $39.00 | $63.00 | 0.6x | -99% |
Average P/E for displayed period: 65.3x
Full ARWR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ARWR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARWR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARWR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARWR — Frequently Asked Questions
Quick answers to the most common questions about buying ARWR stock.
Is ARWR stock overvalued or undervalued?
ARWR trades at -6389.3x P/E, below its 5-year average of 65.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ARWR's valuation compare to peers?
Arrowhead Pharmaceuticals, Inc. P/E of -6389.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ARWR's PEG ratio?
ARWR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1999-2026.